Description: VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Home Page: www.vynetherapeutics.com
VYNE Technical Analysis
520 U.S. Highway 22
Bridgewater,
NJ
08807
United States
Phone:
800 775 7936
Officers
| Name | Title |
|---|---|
| Mr. David T. Domzalski | CEO, Pres & Director |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Ms. Mutya Harsch J.D. | Gen. Counsel, Chief Legal Officer & Company Sec. |
| Mr. Tyler Zeronda | CFO, Principal Accounting Officer & Treasurer |
| Mr. David Schuz | Sr. VP of Intellectual Property |
| Dr. Russell Elliott D.Phil. | Sr. VP of Pharmaceutical Devel. |
| Dr. Darrell S. Rigel M.S., M.D., MS | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2433 |
| Price-to-Sales TTM: | 0.6757 |
| IPO Date: | 2018-01-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |